Related content

Imatinib mesylate (STI-571 Glivec(R), Gleevec(TM)) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target - Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study

By Verweij J.   van Oosterom A.   Blay J.-Y.   Judson I.   Rodenhuis S.   van der Graaf W.   Radford J.   Le Cesne A.   Hogendoorn P.C.W.   di Paola E.D.   Brown M.   Nielsen O.S.  

European Journal of Cancer, Vol. 39, Iss. 14, 2003-09 ,pp. : 2006-2011

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

By Dutreix Catherine   Peng Bin   Mehring Guenther   Hayes Michael   Capdeville Renaud   Pokorny Rolf   Seiberling Michael  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 290-294

Springer Publishing Company

Access to resources Recommend Favorite

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

By Hamilton Marta   Wolf Julie   Drolet Daniel   Fettner Scott   Rakhit Ashok   Witt Karsten   Lum Bert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 613-621

Springer Publishing Company

Access to resources Recommend Favorite

STI571 - a magic bullet?

By Verweij J.   Judson I.   van Oosterom A.  

European Journal of Cancer, Vol. 37, Iss. 15, 2001-10 ,pp. : 1816-1819

Elsevier

Access to resources Recommend Favorite

Keratoacanthomas associated with imatinib mesylate

By Balagula Yevgeniy   Busam Klaus J.   Carvajal Richard D.   Wolchok Jedd D.   Myskowski Patricia L.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 593-595

Informa Healthcare

Access to resources Recommend Favorite